1. Biochemistry and Chemical Biology
  2. Structural Biology and Molecular Biophysics
Download icon

Membrane Proteins: Capturing the signal

  1. Jee-Young Mock
  2. William M Clemons Jr  Is a corresponding author
  1. California Institute of Technology, United States
  • Cited 0
  • Views 1,509
  • Annotations
Cite this article as: eLife 2015;4:e09315 doi: 10.7554/eLife.09315


High-resolution structures provide new insights into how an RNA-protein complex recognizes the signal that targets membrane proteins to the endoplasmic reticulum before they aggregate.

Main text

About a quarter of eukaryotic genes encode membrane proteins, many of which perform activities that are essential for cells to survive (Wallin and von Heijne, 1998). Nevertheless, the production of these proteins poses a problem for the cell. Like all proteins, membrane proteins are built by ribosomes within the cytosol, which is an aqueous and crowded environment (Ellis, 2001). However, the transmembrane domains of membrane proteins are hydrophobic (or ‘water-hating’) and are therefore prone to aggregating in such an environment. This means that they must be promptly sent to their destination. For most eukaryotic membrane proteins, this destination is the membrane of the endoplasmic reticulum.

In 1971, Blobel and Sabitini proposed a possible solution to this problem: the proteins that are destined for the endoplasmic reticulum (i.e., membrane proteins and secreted proteins) contain a signal peptide that is recognized by the ribosome. Subsequent studies confirmed the existence of this signal peptide (Blobel and Dobberstein, 1975), and the signal recognition particle (SRP), which actively targets the proteins to the endoplasmic reticulum, was also eventually identified (Walter and Blobel, 1981a).

The SRP is thought to bind to and protect the signal peptide (which is typically also the first transmembrane domain for membrane proteins) when it emerges from the ribosome. This halts the building of the protein until the entire complex (including the ribosome, the SRP, the messenger RNA and the newly forming protein) arrives at the membrane of the endoplasmic reticulum. Although this process has been extensively characterized since its discovery, several important details of the molecular interplay between the mammalian ribosome and the SRP remain elusive. Our current structural understanding of the SRP-ribosome complex in eukaryotes has been limited to a 7.4-Å reconstruction of an artificial complex formed by a plant ribosome and a mammalian SRP (Halic et al., 2006). It also remains unclear how and when the SRP is recruited to the ribosome. Now, in eLife, Rebecca Voorhees and Ramanujan Hegde from the MRC Laboratory of Molecular Biology report new insights into how a mammalian SRP interacts with the mammalian ribosome to recognize the signal peptide (Voorhees and Hegde, 2015).

First, Voorhees and Hegde examined precisely when the SRP binds by using shortened versions of messenger RNA molecules to trap the SRP-ribosome complex at distinct points in the translation of a membrane protein. A ‘scanning’ state was captured while the first transmembrane domain was inside the ribosome; and an ‘engaged’ state was captured when the SRP gained access to the transmembrane domain after it had emerged from the ribosome (Figure 1). Voorhees and Hegde then used electron cryo-microscopy (cryo-EM) to visualize the scanning and engaged complexes to resolutions of 3.8 Å and 3.9 Å, respectively: these are the highest resolution reconstructions of the SRP-ribosome complex to date. These data suggest that for membrane proteins, the SRP is recruited to the ribosome before the signal peptide emerges, as first proposed 20 years ago (Ogg and Walter, 1995). Importantly, this ‘anticipatory binding’ seems to be specific for the signal peptides of membrane proteins, which are slightly longer than the signal peptides of secreted proteins.

Recruitment of the signal recognition particle (SRP) to a ribosome translating a membrane protein.

(1) Ribosomes that are not building proteins destined for the endoplasmic reticulum do not recruit the SRP (shown in green). (2) Membrane proteins have hydrophobic segments (called transmembrane domains) that are eventually inserted into the membrane. Exposing these transmembrane domains in the aqueous cytosol can be detrimental to the cell. The first transmembrane domain acts as a ‘signal peptide’ (shown in magenta), and flags the ribosome and the newly forming protein chain for delivery to the membrane of the endoplasmic reticulum. Voorhees and Hegde have confirmed that the SRP binds the ribosome while this signal peptide is still inside the ribosome ensuring that the transmembrane domain is never exposed to the aqueous environment. This is referred to as the ‘scanning’ state. (3) When the signal peptide emerges from the ribosome it becomes accessible for binding to the SRP. The SRP undergoes a conformational change in order to accommodate the transmembrane domain, and protect it from the cytosol. This is called the ‘engaged’ state, and the entire complex is then delivered to the membrane of the endoplasmic reticulum.

These results raise a perplexing question. The classical model suggests that SRP binding would lock the ribosome into a conformation that is incompatible with the binding of other molecules called translational factors, which are needed for translation of the messenger RNA to occur (Halic et al., 2004). So how does the SRP remain bound to the ribosome before and after the emergence of the signal peptide, during which time the protein is still being translated? It should be noted that the artificial plant ribosome-mammalian SRP complex arrests translation more strongly than the naturally occurring complex (Walter and Blobel, 1981b; Wolin and Walter, 1989). Intriguingly, Voorhees and Hegde observe a stable three-part complex between the SRP, the ribosome and a translational factor. This lends support to the idea that SRP binding and translation are not mutually exclusive events under physiological conditions.

The new high-resolution structures also reveal that the hitherto unresolved portion of the SRP subunit that binds to the signal peptide contains two additional helices. These helices have at least two distinct roles. First, they occupy the hydrophobic groove of the substrate-binding domain of the SRP before it engages with the signal peptide. Second, they provide a protective lid for the signal peptide when it binds to the SRP. This finding sheds light on how the part of the SRP that binds to the signal peptide remains protected from the aqueous cytosol, which was unclear from previous structural studies (Keenan et al., 1998; Halic et al., 2004).

Since the first low-resolution cryo-EM reconstruction of the eukaryotic ribosome almost 20 years ago (Verschoor et al., 1996), rapid advances in data collection and processing have revolutionized the field, with the bacterial ribosome now resolved up to 2.9 Å (Fischer et al., 2015). Voorhees and Hegde combine this powerful tool with elegant biochemical methods to reveal how the SRP scans and captures the signal peptide. The data presented here not only challenge and refine the previous model of SRP-mediated targeting, they also motivate more questions. Namely, the lack of drastic conformational changes in the ribosome makes it clear that the signal peptide must trigger a more subtle change. What is the nature of this change, and how is it recognized by the SRP? The exciting combination of cryo-EM and biochemistry will help further refine the model for capturing the signal in the near future.


Article and author information

Author details

  1. Jee-Young Mock

    Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4656-3357
  2. William M Clemons Jr

    Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, United States
    For correspondence
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0021-889X

Publication history

  1. Version of Record published: July 9, 2015 (version 1)


© 2015, Mock and Clemons

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 1,509
    Page views
  • 139
  • 0

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Xiao-Tong Lin et al.
    Research Article Updated

    Dysregulation of tumor-relevant proteins may contribute to human hepatocellular carcinoma (HCC) tumorigenesis. FBXO45 is an E3 ubiquitin ligase that is frequently elevated expression in human HCC. However, it remains unknown whether FBXO45 is associated with hepatocarcinogenesis and how to treat HCC patients with high FBXO45 expression. Here, IHC and qPCR analysis revealed that FBXO45 protein and mRNA were highly expressed in 54.3% (57 of 105) and 52.2% (132 of 253) of the HCC tissue samples, respectively. Highly expressed FBXO45 promoted liver tumorigenesis in transgenic mice. Mechanistically, FBXO45 promoted IGF2BP1 ubiquitination at the Lys190 and Lys450 sites and subsequent activation, leading to the upregulation of PLK1 expression and the induction of cell proliferation and liver tumorigenesis in vitro and in vivo. PLK1 inhibition or IGF2BP1 knockdown significantly blocked FBXO45-driven liver tumorigenesis in FBXO45 transgenic mice, primary cells, and HCCs. Furthermore, IHC analysis on HCC tissue samples revealed a positive association between the hyperexpression of FBXO45 and PLK1/IGF2BP1, and both had positive relationship with poor survival in HCC patients. Thus, FBXO45 plays an important role in promoting liver tumorigenesis through IGF2BP1 ubiquitination and activation, and subsequent PLK1 upregulation, suggesting a new strategy for treating HCC by targeting FBXO45/IGF2BP1/PLK1 axis.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Rania Elsabrouty et al.
    Research Article Updated

    UbiA prenyltransferase domain-containing protein-1 (UBIAD1) utilizes geranylgeranyl pyrophosphate (GGpp) to synthesize the vitamin K2 subtype menaquinone-4. The prenyltransferase has emerged as a key regulator of sterol-accelerated, endoplasmic reticulum (ER)-associated degradation (ERAD) of HMG CoA reductase, the rate-limiting enzyme in synthesis of cholesterol and nonsterol isoprenoids including GGpp. Sterols induce binding of UBIAD1 to reductase, inhibiting its ERAD. Geranylgeraniol (GGOH), the alcohol derivative of GGpp, disrupts this binding and thereby stimulates ERAD of reductase and translocation of UBIAD1 to Golgi. We now show that overexpression of Type 1 polyisoprenoid diphosphate phosphatase (PDP1), which dephosphorylates GGpp and other isoprenyl pyrophosphates to corresponding isoprenols, abolishes protein geranylgeranylation as well as GGOH-induced ERAD of reductase and Golgi transport of UBIAD1. Conversely, these reactions are enhanced in the absence of PDP1. Our findings indicate PDP1-mediated hydrolysis of GGpp significantly contributes to a feedback mechanism that maintains optimal intracellular levels of the nonsterol isoprenoid.